-
Views
-
Cite
Cite
L. Peramiquel, L. Puig, J. Dalmau, E. Ricart, E. Roé, A. Alomar, Onset of flexural psoriasis during infliximab treatment for Crohn's disease, Clinical and Experimental Dermatology, Volume 30, Issue 6, 1 November 2005, Pages 713–714, https://doi.org/10.1111/j.1365-2230.2005.01882.x
Close - Share Icon Share
Extract
Conflict of interest: none declared.
Infliximab is a monoclonal antibody that binds and inactivates tumour necrosis factor (TNF)‐α. It has been successfully used in the management of diseases associated with a Th1 profile (interleukin‐1, TNF‐α and interferon‐γ) such as Crohn's disease (CD), rheumatoid arthritis and psoriasis.
We report a case of predominantly flexural psoriasis that paradoxically appeared during infliximab treatment for CD.
A 29‐year‐old woman was referred in October 2003 for evaluation of approx. 10 slightly erythematous papules and plaques with peripheral scaling, suggestive of pityriasis rosea, which had appeared on her trunk during the previous week. Her past medical history revealed that she had been diagnosed with CD 3 years previously, with gastric, duodenal, distal ileum, caecal, colon and, at the present time, intense perianal involvement. She also experienced arthralgias and had become corticoresistant. She had been previously treated with methotrexate, celecoxib, azathioprine and, lately, infliximab (5 mg/kg intravenously; nine doses since January 2002). She did not have any personal or familial history of psoriasis.
